Favaretto, A., Grossi, F., Morabito, A. and Ravasio, R. 2017. Costs of adverse events associated with afatinib, erlotinib, and gefitinib first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations: Il Costo Degli Eventi Avversi Associati ad Afatinib, Erlotinib e Gefitinib Nel Trattamento del Tumore del Polmone non a Piccole Cellule con Mutazione EGFR. Global and Regional Health Technology Assessment. 4, 1 (Jul. 2017), 187–196. DOI:https://doi.org/10.33393/grhta.2017.394.